Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/76661
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Tang, W. | - |
dc.contributor.author | McDonald, S. | - |
dc.contributor.author | Hawley, C. | - |
dc.contributor.author | Badve, S. | - |
dc.contributor.author | Boudville, N. | - |
dc.contributor.author | Brown, F. | - |
dc.contributor.author | Clayton, P. | - |
dc.contributor.author | Campbell, S. | - |
dc.contributor.author | de Zoysa, J. | - |
dc.contributor.author | Johnson, D. | - |
dc.date.issued | 2013 | - |
dc.identifier.citation | Nephrology Dialysis Transplantation, 2013; 28(2):455-461 | - |
dc.identifier.issn | 0931-0509 | - |
dc.identifier.issn | 1460-2385 | - |
dc.identifier.uri | http://hdl.handle.net/2440/76661 | - |
dc.description.abstract | Background: There are few reports regarding the long-term renal replacement therapy (RRT) outcomes of amyloidosis. Methods: In this retrospective, multi-centre, multi-country registry analysis, all patients with and without amyloidosis who commenced RRT for end-stage renal failure (ESRF) in Australia and New Zealand between 1963 and 2010 were included. Results: Of 58 422 patients who underwent RRT during the study period, 490 (0.8%) had ESRF secondary to amyloidosis. The median survival of amyloidosis patients on dialysis (2.09 years, 95% CI 1.85–2.32 years) was significantly inferior to that of patients with other causes of ESRF (4.45 years, 95% CI 4.39–4.51 years) (log-rank score 242, P < 0.001). The survival of amyloidosis patients receiving peritoneal dialysis (1.9 years, 95% CI 1.58–2.22) was comparable with those receiving haemodialysis (2.17 years, 95% CI 1.89–2.45) (P = 0.18). Fifty-three (13.8%) amyloidosis patients died of amyloidosis complications. Forty-six patients underwent renal transplantation with first graft survival rates of 45% at 5 years and 26% at 10 years. Nine (16.4%) patients experienced amyloidosis recurrence in their allografts, which led to graft failure in six patients. ESRF patients with amyloidosis experienced inferior median first renal allograft survival (4.55 years, 95% CI 1.96–7.15 versus 10.7 years, 95% CI 10.5–11.0, P = 0.001) and transplant patient survival (6.03 years, 95% CI 2.71–9.36 versus 16.8 years, 95% CI 16.4–17.1, P < 0.001) compared with patients with other causes of ESRF. Respective 10-year patient survival rates were 37 and 69%. Conclusions: Amyloidosis was associated with poor patient survival following dialysis and/or renal transplantation, poor renal allograft survival and a significant incidence of disease recurrence in the allograft. An appreciable proportion of amyloid ESRF patients died of amyloidosis-related complications. | - |
dc.description.statementofresponsibility | Wen Tang, Stephen P. McDonald, Carmel M. Hawley, Sunil V. Badve, Neil Boudville, Fiona G. Brown, Philip A. Clayton, Scott B. Campbell, Janak R. de Zoysa and David W. Johnson | - |
dc.language.iso | en | - |
dc.publisher | Oxford Univ Press | - |
dc.rights | © The Author 2012. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. | - |
dc.source.uri | http://dx.doi.org/10.1093/ndt/gfs492 | - |
dc.subject | amyloidosis | - |
dc.subject | end-stage renal failure | - |
dc.subject | outcomes | - |
dc.subject | recurrence | - |
dc.subject | renal transplantation | - |
dc.title | End-stage renal failure due to amyloidosis: outcomes in 490 ANZDATA registry cases | - |
dc.type | Journal article | - |
dc.identifier.doi | 10.1093/ndt/gfs492 | - |
pubs.publication-status | Published | - |
dc.identifier.orcid | McDonald, S. [0000-0001-6103-1386] | - |
dc.identifier.orcid | Clayton, P. [0000-0001-9190-6753] | - |
Appears in Collections: | Aurora harvest 4 Public Health publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.